Wells Fargo & Company Forecasts Strong Price Appreciation for LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular (NASDAQ:LMAT) had its target price upped by equities research analysts at Wells Fargo & Company from $87.00 to $94.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target would indicate a potential downside of 13.11% from the stock’s previous close.

A number of other brokerages also recently issued reports on LMAT. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Citizens Jmp upped their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $105.80.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $108.18 on Thursday. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $115.33. The firm has a market capitalization of $2.45 billion, a P/E ratio of 43.10, a PEG ratio of 2.30 and a beta of 0.72. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $87.02 and a 200-day moving average price of $88.40.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. The firm’s revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after buying an additional 21,946 shares during the last quarter. First Trust Advisors LP grew its stake in LeMaitre Vascular by 13.4% during the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after acquiring an additional 111,193 shares in the last quarter. Geneva Capital Management LLC increased its holdings in LeMaitre Vascular by 6.0% in the 2nd quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after acquiring an additional 51,489 shares during the last quarter. State Street Corp lifted its stake in LeMaitre Vascular by 0.8% in the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after purchasing an additional 6,130 shares in the last quarter. Finally, Congress Asset Management Co. boosted its holdings in shares of LeMaitre Vascular by 5.8% during the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after purchasing an additional 40,065 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and above‑consensus guidance: LeMaitre reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.); management raised Q1 and FY2026 EPS and revenue guidance, signaling continued top‑line momentum. Press Release
• Positive Sentiment: Dividend increase: Company raised the quarterly dividend 25% to $0.25/share (ex‑dividend March 12), returning cash to shareholders and supporting income‑oriented demand.
• Positive Sentiment: Analyst bullishness: Multiple firms raised ratings/targets — Citizens JMP to $118 (market outperform) and Roth MKM reaffirmed Buy and raised target to $117 — these are constructive for sentiment. Analyst Note
• Neutral Sentiment: Investor outreach: Management will participate in five investor conferences in March, increasing visibility and allowing direct Q&A with investors. Conference Notice
• Neutral Sentiment: Earnings call coverage and transcripts are available for deeper color on drivers (procedure volumes, product mix, backlog) for investors doing fundamental diligence. Earnings Transcript
• Negative Sentiment: Mixed analyst targets; some firms still imply downside: Wells Fargo raised its target but keeps an “equal weight” rating with a $94 target (below current price), and a few targets remain lower than the stock’s recent level — this can trigger profit‑taking or short‑term selling. Analyst Notes

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.